Clinical trial · Interventional
Trial of Quercetin in the Treatment and Prevention of Chemotherapy-induced Neuropathic Pain in Cancer Patients
Prospective Open Labeled Pilot Trial of Quercetin in the Treatment and Prevention of Chemotherapy-induced Neuropathic Pain in Cancer Patients
NCT02989129CI-TRIAL-00032559withdrawnEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): FDA IND Approval
Summary
Brief summary (as posted)
The goal of this clinical research study is to learn about the effectiveness of quercetin in treating and preventing CINP. Researchers also want to learn if quercetin has an effect on participant's quality of life.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemotherapy Induced Neuropathic Pain | — | UNRESOLVED | — |
| Polyneuropathies and Other Disorders of the Peripheral Nervous System | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Quercetin | Drug | — | UNRESOLVED |
| Questionnaires | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Chemotherapy Induced Neuropathic Pain (CINP) Treatment Group
- description
- Questionnaires completed at Baseline and at End of Study Visit. Participants take Quercetin tablets by mouth 2 times every day for 12 weeks.
- interventionNames
- Behavioral: Questionnaires
- Drug: Quercetin
- type
- EXPERIMENTAL
- label
- Chemotherapy Induced Neuropathic Pain (CINP) Prevention Group
- description
- Questionnaires completed at Baseline and at End of Study Visit. Participants take Quercetin tablets by mouth 2 times every day for 12 weeks.
- interventionNames
- Behavioral: Questionnaires
- Drug: Quercetin
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients \> 18 years old. 2. Patients starting, undergoing or completed chemotherapy at MD Anderson Cancer Center 3. Any cancer patients who received any of the chemotherapeutic agents listed below and developed neuropathic pain for the treatment cohort; or any cancer patients who have been scheduled to receive any of the chemotherapeutic agents listed below for the preventive cohort. The chemotherapeutic agents include 1) taxanes (paclitaxel, docetaxel), 2) vinca alkaloids (vincristine, vinblastine), 3) platinum agents (cisplatin, carboplatin, oxaliplatin), and 4) others (thalidomide, bortezomib, lenalidomide). 4. Patients have neuropathic pain intensity of at least 4/10 on numeric rating score (NRS, 0/10 being no pain and 10/10 excruciating pain) for the treatment cohort; or 0/10 on NRS for the preventive cohort. 5. Patients are on stable dose of any medication 6. Patients followed at the Pain Medicine department. Patients with normal renal function (Normal values, BUN (blood urea nitrogen): 8 to 20 mg/dL, Creatinine: 0.7 to 1.3 mg/dL). 7. Patients able to speak English. 8. Patients able to review, understand, and provide written consent. 9. Patients with an Eastern Cooperative Oncology performance (ECOG) status of 0-2. Exclusion Criteria: 1. Renal impairment. 2. Pregnancy. 3. Hypersensitivity reaction, anaphylaxis, or any other serious adverse reaction to quercetin or product components. 4. Patients who are enrolled in another Pain Medicine trial. 5. Patients with malabsorption syndrome or resection of the stomach or small bowel. 6. Patients with any condition that precludes use of the study medication as determined by the treating physician. 7. Patients taking Quercetin for other medical reasons. 8. Patients taking Digoxin.
References
Publications (0)
Data not yet available
No reference posted for this study.